Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Neha Pagidipati CV

Associate Professor of Medicine
Medicine, Cardiology
CV

Selected Grants


VictORION-Inclusion

Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2023 - 2027

Cardio Health Alliance: Test to Treat

Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2023 - 2025

A Controlled trial to improve use of High IntEnsity statins for Vascular protEction: ACHIEVE

ResearchCo Investigator · Awarded by National Institutes of Health · 2023 - 2025

NOVA-LATAM Lipid Management - Industry

Clinical TrialPrincipal Investigator · Awarded by Novartis Farmaceutica SA de CV · 2022 - 2024

Impact of a food purchasing intervention on consumption patterns and improved dietary outcomes in New Orleans

ResearchCo Investigator · Awarded by American Heart Association · 2023 - 2024

VictORION-Inclusion

Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2023 - 2027

Cardio Health Alliance: Test to Treat

Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2023 - 2025

A Controlled trial to improve use of High IntEnsity statins for Vascular protEction: ACHIEVE

ResearchCo Investigator · Awarded by National Institutes of Health · 2023 - 2025

NOVA-LATAM Lipid Management - Industry

Clinical TrialPrincipal Investigator · Awarded by Novartis Farmaceutica SA de CV · 2022 - 2024

Impact of a food purchasing intervention on consumption patterns and improved dietary outcomes in New Orleans

ResearchCo Investigator · Awarded by American Heart Association · 2023 - 2024

ESTABLISHING A METABOLIC PLATFORM TO CHARACTERIZE A COHORT AND STREAMLINE TRIALS

ResearchPrincipal Investigator · Awarded by Eli Lilly and Company · 2023 - 2024

BI - CKD PHSR Study

Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Corporation · 2021 - 2023

Dissemination and Implementation Science in Cardiovascular Outcomes (DISCO)

Inst. Training Prgm or CMEScholar · Awarded by National Institutes of Health · 2017 - 2023

ASCVD EHR Cohort - CardioHealth Alliance Project

Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2022 - 2023

PHENO (BI Heart Failure Implementation Project )

Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Corporation · 2021 - 2023

LEADER Trial: Association between weight change and cardiometabolic risk factors in a real-world population of U.S. Adults

Clinical TrialPrincipal Investigator · Awarded by Novo Nordisk, Inc. · 2019 - 2022

Landscape Analysis -BI US CKD Study

Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2022 - 2022

ATHERO Alliance Learning Lab

ResearchPrincipal Investigator · Awarded by NOVARTIS DE COLOMBIA S.A. · 2022 - 2022

Data Characterization of DUHS data for Amgen project

ResearchPrincipal Investigator · Awarded by Amgen, Inc. · 2019 - 2021

Characterization of Lp(a) Testing in a Network Consortium

ResearchPrincipal Investigator · Awarded by Amgen, Inc. · 2020 - 2021

QuBBD: Deep Poisson Methods for Biomedical Time-to-Event and Longitudinal Data

ResearchInvestigator · Awarded by National Institutes of Health · 2017 - 2021

Cardiovascular Risk Profile of LAL Deficiency Patients

ResearchFellow · Awarded by Alexion Pharmaceuticals, Inc. · 2016 - 2020

External Relationships


  • Amgen, Inc.
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim/Lilly alliance
  • Boehringer Ingleheim
  • Amgen, Inc.
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim/Lilly alliance
  • Boehringer Ingleheim
  • Crispr Therapeutics
  • Esperion
  • Johnson & Johnson
  • Merck
  • Miga Health
  • Novartis pharmaceuticals
  • Novo Nordisk

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.